Background. With the implementation of outpatient (ambulatory) decentralised rifampicin-resistant tuberculosis (RR-TB) treatment in South Africa (SA) since late 2011, the high rates of loss from treatment are a significant concern. Missed appointments lead to treatment interruptions and may contribute to amplification of resistance, ongoing transmission of RR-TB and an increased risk of morbidity and mortality to the patient.Objective. To describe characteristics of patients who missed scheduled appointments during ambulatory RR-TB treatment.Methods. The study was a retrospective, deidentified electronic medical record review of RR-TB patients at an outpatient clinic in Johannesburg, SA, from March 2013 to December 2014. Associations betwee...
In South Africa, roughly half of the drug-resistant TB cases diagnosed are reported to have been sta...
Abstract Background According to the World Health Organization, South Africa ranks as one of the hig...
Abstract Background In 2011, South Africa improved its ability to test for rifampicin-resistant TB (...
Setting Khayelitsha, South Africa, with high burdens of rifampicin-resistant tuberculosis (RR-TB) an...
Khayelitsha, South Africa, with high burdens of rifampicin-resistant tuberculosis (RR-TB) and HIV co...
Khayelitsha, South Africa, with high burdens of rifampicin-resistant tuberculosis (RR-TB) and HIV co...
BACKGROUND: In the "Centre National Hospitalier de Pneumo-Phtisiologie" of Cotonou, Benin, little is...
BACKGROUND: South Africa has a large burden of rifampicin-resistant tuberculosis (RR-TB), with 18,73...
Background: South Africa has a large burden of rifampicin-resistant tuberculosis (RR-TB), with 18,7...
Background: South Africa has a large burden of rifampicin-resistant tuberculosis (RR-TB...
Background: South Africa has a large burden of rifampicin-resistant tuberculosis (RR-TB...
Background: South Africa has a large burden of rifampicin-resistant tuberculosis (RR-TB), with 18,7...
We describe baseline characteristics, time to treatment initiation and interim patient outcomes at a...
SETTING: Hlabisa Tuberculosis Programme, Hlabisa, South Africa. OBJECTIVE: To determine trends in an...
In South Africa, roughly half of the drug-resistant TB cases diagnosed are reported to have been sta...
In South Africa, roughly half of the drug-resistant TB cases diagnosed are reported to have been sta...
Abstract Background According to the World Health Organization, South Africa ranks as one of the hig...
Abstract Background In 2011, South Africa improved its ability to test for rifampicin-resistant TB (...
Setting Khayelitsha, South Africa, with high burdens of rifampicin-resistant tuberculosis (RR-TB) an...
Khayelitsha, South Africa, with high burdens of rifampicin-resistant tuberculosis (RR-TB) and HIV co...
Khayelitsha, South Africa, with high burdens of rifampicin-resistant tuberculosis (RR-TB) and HIV co...
BACKGROUND: In the "Centre National Hospitalier de Pneumo-Phtisiologie" of Cotonou, Benin, little is...
BACKGROUND: South Africa has a large burden of rifampicin-resistant tuberculosis (RR-TB), with 18,73...
Background: South Africa has a large burden of rifampicin-resistant tuberculosis (RR-TB), with 18,7...
Background: South Africa has a large burden of rifampicin-resistant tuberculosis (RR-TB...
Background: South Africa has a large burden of rifampicin-resistant tuberculosis (RR-TB...
Background: South Africa has a large burden of rifampicin-resistant tuberculosis (RR-TB), with 18,7...
We describe baseline characteristics, time to treatment initiation and interim patient outcomes at a...
SETTING: Hlabisa Tuberculosis Programme, Hlabisa, South Africa. OBJECTIVE: To determine trends in an...
In South Africa, roughly half of the drug-resistant TB cases diagnosed are reported to have been sta...
In South Africa, roughly half of the drug-resistant TB cases diagnosed are reported to have been sta...
Abstract Background According to the World Health Organization, South Africa ranks as one of the hig...
Abstract Background In 2011, South Africa improved its ability to test for rifampicin-resistant TB (...